drugset
drugset / Trial / NCT06613373

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

NCT06613373 ↗

Phase 4 Not yet recruiting 30 enrolled Jiangsu Famous Medical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, exploratory clinical study

Timeline

Start
2024-10-15
Primary completion
2025-10-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule 150 mg Oral

Indications

breast cancer